Li M, Liu J, Shi L, Zhou C, Zou M, Fu D
Bioact Mater. 2023; 25:95-106.
PMID: 36789001
PMC: 9900456.
DOI: 10.1016/j.bioactmat.2023.01.015.
Senekowitsch S, Schick P, Abrahamsson B, Augustijns P, Giessmann T, Lennernas H
Pharmaceutics. 2022; 14(4).
PMID: 35456635
PMC: 9025904.
DOI: 10.3390/pharmaceutics14040801.
Cirillo D, Sarowar S, Enger P, Bjorsvik H
ChemMedChem. 2021; 16(17):2650-2668.
PMID: 33847044
PMC: 8518981.
DOI: 10.1002/cmdc.202100204.
Murray A, Nguyen T, Parker C, Feagan B, MacDonald J
Cochrane Database Syst Rev. 2020; 8:CD000544.
PMID: 32856298
PMC: 8094989.
DOI: 10.1002/14651858.CD000544.pub5.
Murray A, Nguyen T, Parker C, Feagan B, MacDonald J
Cochrane Database Syst Rev. 2020; 8:CD000543.
PMID: 32786164
PMC: 8189994.
DOI: 10.1002/14651858.CD000543.pub5.
Metabolic Profiling of Human Gastric Cancer Cells Treated With Salazosulfapyridine.
Takizawa K, Muramatsu K, Maruyama K, Urakami K, Sugino T, Kusuhara M
Technol Cancer Res Treat. 2020; 19:1533033820928621.
PMID: 32715923
PMC: 7385828.
DOI: 10.1177/1533033820928621.
Gut microbiota-driven drug metabolism in inflammatory bowel disease.
Crouwel F, Buiter H, de Boer N
J Crohns Colitis. 2020; .
PMID: 32652007
PMC: 7904070.
DOI: 10.1093/ecco-jcc/jjaa143.
The gut microbiome: an orchestrator of xenobiotic metabolism.
Collins S, Patterson A
Acta Pharm Sin B. 2020; 10(1):19-32.
PMID: 31998605
PMC: 6984741.
DOI: 10.1016/j.apsb.2019.12.001.
Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents.
Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y
J Clin Med. 2019; 8(12).
PMID: 31810227
PMC: 6970226.
DOI: 10.3390/jcm8122109.
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Wang Y, Parker C, Feagan B, MacDonald J
Cochrane Database Syst Rev. 2016; (5):CD000544.
PMID: 27158764
PMC: 7045447.
DOI: 10.1002/14651858.CD000544.pub4.
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y, Parker C, Bhanji T, Feagan B, MacDonald J
Cochrane Database Syst Rev. 2016; 4:CD000543.
PMID: 27101467
PMC: 7045743.
DOI: 10.1002/14651858.CD000543.pub4.
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?.
Ye B, van Langenberg D
World J Gastrointest Pharmacol Ther. 2015; 6(4):137-44.
PMID: 26558148
PMC: 4635154.
DOI: 10.4292/wjgpt.v6.i4.137.
Fucosylated multiwalled carbon nanotubes for Kupffer cells targeting for the treatment of cytokine-induced liver damage.
Gupta R, Mehra N, Jain N
Pharm Res. 2013; 31(2):322-34.
PMID: 24043294
DOI: 10.1007/s11095-013-1162-9.
Effects of processing on the release profiles of matrix systems containing 5-aminosalicylic acid.
Korbely A, Kelemen A, Kasa Jr P, Pintye-Hodi K
AAPS PharmSciTech. 2012; 13(4):1341-7.
PMID: 23054987
PMC: 3513469.
DOI: 10.1208/s12249-012-9861-9.
The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.
Gut. 1973; 14(8):637-41.
PMID: 18668841
PMC: 1412752.
DOI: 10.1136/gut.14.8.637.
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.
Fernandez-Becker N, Moss A
Drugs. 2008; 68(8):1089-103.
PMID: 18484800
DOI: 10.2165/00003495-200868080-00006.
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart B, Ware J, Tirona R, Ho R, Leake B, Schwarz U
Pharmacogenet Genomics. 2008; 18(5):439-48.
PMID: 18408567
PMC: 4043148.
DOI: 10.1097/FPC.0b013e3282f974dc.
Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.
Rust C, Bauchmuller K, Bernt C, Vennegeerts T, Fickert P, Fuchsbichler A
Gut. 2005; 55(5):719-27.
PMID: 16322111
PMC: 1856116.
DOI: 10.1136/gut.2005.077461.
Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed M, Dijkmans B
Drugs. 2005; 65(5):661-94.
PMID: 15748099
DOI: 10.2165/00003495-200565050-00006.
Comparative tolerability of therapies for ulcerative colitis.
Ardizzone S, Porro G
Drug Saf. 2002; 25(8):561-82.
PMID: 12113642
DOI: 10.2165/00002018-200225080-00003.
